A股異動 | 華陽國際漲停 聯手中望軟件 共同打造國產BIM軟件
格隆匯2月18日丨華陽國際高開高走,現已封死漲停板,報20.08元,總市值39億元。華陽國際昨晚公告稱,公司與中望軟件於當日簽訂《關於成立合資公司之合資協議》,擬共同出資設立合資公司,開展“國產BIM(建築信息模型)產品研發和軟件銷售”業務。華陽國際表示,本次設立合資公司,將依託中望軟件在工業軟件研發領域的優勢,與華陽國際在建築設計行業豐富的應用場景及應用軟件研發的經驗,共同開展BIM(建築信息模型)軟件研發。本次合作有利於加快公司BIM應用軟件的商業化進程,有助於提高公司市場競爭力,加快公司科技轉型,符合公司的發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.